Delcath Systems, Inc. ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced an update to the ...

Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...

Acute and chronic treatment for hepatic encephalopathy acquired from Mallinckrodt Pharmaceuticals in September 2024Extended pre-clinical, ...

Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its ...

Delcath Systems markets Hepzato Kit for the treatment of uveal melanoma with unresectable hepatic metastases. Click here to read my analysis of DCTH stock.

Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...

Medications are the mainstay of treatment for multiple sclerosis (MS). Many of them are used to block the immune system's attack on the nerves and slow or prevent progression and relapses (flare-ups) ...

The drug is contraindicated in patients taking strong CYP3A inhibitors and should be avoided in those with severe hepatic impairment (Child-Pugh Class C). Journavx is supplied as a 50mg tablet. The ...

Even today, 30% of drug candidates fail in clinical trials, and 18% of these failures are attributed to hepatotoxicity concerns 1. Existing methods to assess human drug-induced liver injury (DILI ...